Study: NCT01389427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 75 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 75 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel 75 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).